Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (85)

« Back to Publications

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.

O'Connor D. et al, (2025), Nat Commun, 16

novel whole blood assay to quantify the release of T cell associated cytokines in response to Bordetella pertussis antigens.

Pinto MV. et al, (2024), J Immunol Methods, 534

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.

Maytum A. et al, (2024), Pediatr Infect Dis J, 43, 809 - 812

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.

Kelly E. et al, (2023), J Infect, 87, 230 - 241

n adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease.

Dold C. et al, (2023), Sci Transl Med, 15

Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

Shaw RH. et al, (2023), J Infect, 86, 574 - 583

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials

EWER K., (2023), Clinical and Experimental Immunology

Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.

Mentzer AJ. et al, (2023), Nat Med, 29, 147 - 157

Regulatory T cell profiles in patients with N-methyl-ᴅ-aspartate receptor-antibody encephalitis.

Iro MA. et al, (2023), Encephalitis, 3, 15 - 23

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.

Shaw RH. et al, (2022), Lancet Respir Med, 10, 1049 - 1060

Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.

Rollier CS. et al, (2022), Vaccine, 40, 4453 - 4463

n exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Marchevsky NG. et al, (2022), EBioMedicine, 81

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

Li G. et al, (2022), Lancet, 399, 2212 - 2225

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat Commun, 13

Load More

1
2
3
4
5
6